Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.
Latest Ratings for PYXS
DateFirmActionFromTo Nov 2021B of A SecuritiesInitiates Coverage OnNeutral Nov 2021JefferiesInitiates Coverage OnBuy Nov 2021Credit SuisseInitiates Coverage OnOutperform